Ann: Opthea Completes COAST Final Week 52 Patient Visit, page-11

I like your positivity.

I must admit, I am in 100% agreement ; - OPT is the real deal.

Look, I have criticisms. I suspected information was leaked about the size of the capital raise last May (dropping from 63 cents to 49 cents with zero public info), and yes, I’m still very grumpy about that. There has been overspending by OPT on external consultants, a significant blowout in P3 costs, and excessive free options lavished on medical advisors who, like us retail investors, could have simply purchased on the market; especially since they can read and analyze data better than us.

Yet, these are peripheral complaints. I am still unable to find any real criticisms of the central issue—Is there any information to suggest the drug won’t work? No! The only real question is "how well will it work and for who?" . It will be highly profitable once commercialized, but we simply don't not yet the order of magnitude of that profit.

It has cost $1 billion to get here, and we are in an awfully good place.